secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncology Institute, Inc. (TOI)
CIK:        0001799191
Form:       8-K/A
Filed at:   2023-06-14T23:59:59+00:00
Accession:  0001799191-23-000020
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

The Oncology Institute names Daniel Virnich as CEO, Brad Hively becomes Vice Chairman
--------------------------------------------------------------------------------

- Brad Hively steps down as CEO effective June 30, 2023, becomes Vice Chairman.
- Daniel Virnich, current President, appointed CEO effective June 30, 2023.
- Hively receives salary continuation, COBRA premiums for 12 months, and 50% of 2023 annual bonus at Board discretion.
- All unvested restricted stock units vest through June 30, 2024 per existing vesting schedules.
- Transition was not the result of any disagreement with the Company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799191/000179919123000020/0001799191-23-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799191/000179919123000020/toi-20230608.htm
  HTML page:      https://secwatch.observer/filing/0001799191-23-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer